Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 301 - 350 av 378 resultater
Tid
Selskap
Tittel
Sektor
Kategori
27 Oct 2021
07:00 CEST
IPSEN
Ipsen Pledges Ambitious Action on Climate Change
20103015 Pharmaceuticals
Other subject
27 Oct 2021
07:00 CEST
IPSEN
Ipsen prend de nouveaux engagements ambitieux pour lutter contre le changement climatique
20103015 Pharmaceuticals
Other subject
21 Oct 2021
07:36 CEST
IPSEN
Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance
20103015 Pharmaceuticals
Commercial results
21 Oct 2021
07:36 CEST
IPSEN
Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de l'année et revoit à la hausse ses objectifs financiers pour 2021
20103015 Pharmaceuticals
Commercial results
18 Oct 2021
07:00 CEST
IPSEN
Ipsen intègre un nouveau programme à son portefeuille R&D de produits d’oncologie en phase pré-clinique grâce à une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la protéine modificatrice d’ARN METTL3
20103015 Pharmaceuticals
Alliances and agreements
18 Oct 2021
07:00 CEST
IPSEN
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
20103015 Pharmaceuticals
Alliances and agreements
11 Oct 2021
07:00 CEST
IPSEN
Ipsen nomme Mari Scheiffele en qualité de Vice-Présidente exécutive et Présidente Médecine de spécialité internationale
20103015 Pharmaceuticals
Other subject
11 Oct 2021
07:00 CEST
IPSEN
Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International
20103015 Pharmaceuticals
Other subject
08 Oct 2021
18:00 CEST
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Other subject
08 Oct 2021
18:00 CEST
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Other subject
20 Sep 2021
13:51 CEST
IPSEN
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
20103015 Pharmaceuticals
Other subject
18 Sep 2021
06:30 CEST
IPSEN
Ipsen : ESMO 2021 : Cabometyx® démontre une réduction soutenue de 78 % du risque de progression de la maladie ou de décès chez les patients atteints d’une forme rare de cancer de la thyroïde
20103015 Pharmaceuticals
Other subject
10 Sep 2021
18:00 CEST
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Other subject
10 Sep 2021
18:00 CEST
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Other subject
31 Aug 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 23/08/2021 and 25/08/2021
20103015 Pharmaceuticals
Legal
31 Aug 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 23 au 25 Août 2021
20103015 Pharmaceuticals
Legal
24 Aug 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares between 16/08/2021 and 20/08/2021
20103015 Pharmaceuticals
Legal
24 Aug 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 16 au 20 Août 2021
20103015 Pharmaceuticals
Legal
17 Aug 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 09/08/2021 And 13/08/2021
20103015 Pharmaceuticals
Legal
17 Aug 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 09 au 13 Août 2021
20103015 Pharmaceuticals
Legal
13 Aug 2021
07:00 CEST
IPSEN
Ipsen annonce le retrait de sa demande d’approbation pour le palovarotène et son intention d’en soumettre une nouvelle après des analyses de données complémentaires
20103015 Pharmaceuticals
Other subject
13 Aug 2021
07:00 CEST
IPSEN
Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-submit Following Additional Data Analyses
20103015 Pharmaceuticals
Other subject
10 Aug 2021
18:00 CEST
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Other subject
10 Aug 2021
18:00 CEST
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Other subject
03 Aug 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 26 au 30 Juillet 2021
20103015 Pharmaceuticals
Legal
03 Aug 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 26/07/2021 and 30/07/2021
20103015 Pharmaceuticals
Legal
02 Aug 2021
07:00 CEST
IPSEN
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
20103015 Pharmaceuticals
Other subject
02 Aug 2021
07:00 CEST
IPSEN
Ipsen conclut un partenariat exclusif avec Exicure dans les maladies neurodégénératives rares
20103015 Pharmaceuticals
Other subject
29 Jul 2021
07:00 CEST
IPSEN
Ipsen Delivers Strong H1 2021 Results and Upgrades Full-Year Guidance
20103015 Pharmaceuticals
Sales
29 Jul 2021
07:00 CEST
IPSEN
Ipsen publie de solides résultats pour le premier semestre 2021 et revoit à la hausse ses objectifs pour l’exercice en cours
20103015 Pharmaceuticals
Sales
27 Jul 2021
19:02 CEST
IPSEN
Ipsen renforce son portefeuille en Oncologie en phase pré-clinique grâce à une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une molécule ciblant la voie de l’apoptose
20103015 Pharmaceuticals
Other subject
27 Jul 2021
19:01 CEST
IPSEN
Ipsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway
20103015 Pharmaceuticals
Other subject
27 Jul 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 19/07/2021 And 23/07/2021
20103015 Pharmaceuticals
Legal
27 Jul 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 19 au 23 Juillet 2021
20103015 Pharmaceuticals
Legal
20 Jul 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 12/07/2021 And 16/07/2021
20103015 Pharmaceuticals
Legal
20 Jul 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 12 au 16 Juillet 2021
20103015 Pharmaceuticals
Legal
15 Jul 2021
18:25 CEST
IPSEN
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
20103015 Pharmaceuticals
Other subject
15 Jul 2021
18:25 CEST
IPSEN
Ipsen et IRLAB concluent un accord de licence mondiale exclusif pour améliorer le quotidien de patients atteints de la maladie de Parkinson
20103015 Pharmaceuticals
Other subject
13 Jul 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 05/07/2021 and 09/07/2021
20103015 Pharmaceuticals
Legal
13 Jul 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 05 au 09 Juillet 2021
20103015 Pharmaceuticals
Legal
09 Jul 2021
18:00 CEST
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Other subject
09 Jul 2021
18:00 CEST
IPSEN
Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF
20103015 Pharmaceuticals
Other subject
09 Jul 2021
18:00 CEST
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Other subject
09 Jul 2021
18:00 CEST
IPSEN
Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF
20103015 Pharmaceuticals
Other subject
06 Jul 2021
18:00 CEST
IPSEN
IPSEN : Déclaration des transactions sur actions propres réalisées du 28 juin au 02 Juillet 2021
20103015 Pharmaceuticals
Legal
06 Jul 2021
18:00 CEST
IPSEN
IPSEN: Disclosure Transaction in Own Shares Between 28/06/2021 and 02/07/2021
20103015 Pharmaceuticals
Legal
29 Jun 2021
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 21/06/2021 and 25/06/2021
20103015 Pharmaceuticals
Legal
29 Jun 2021
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 21 au 25 Juin 2021
20103015 Pharmaceuticals
Legal
28 Jun 2021
07:00 CEST
IPSEN
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
20103015 Pharmaceuticals
Other subject
28 Jun 2021
07:00 CEST
IPSEN
Exelixis et Ipsen annoncent que le cabozantinib en association avec un inhibiteur de checkpoint immunitaire a considérablement amélioré la survie sans progression des patients atteints d’un cancer du foie avancé non traité au préalable
20103015 Pharmaceuticals
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
6
7
8
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva